Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
805
datasets available to search
ShareScore release 0.9.0
Dataset results
805 results for “nodulation”
Data from: Physician assessment of pretest probability of malignancy and adherence with guidelines for pulmonary nodule evaluation
The annual incidence of pulmonary nodules is estimated at 1.57 million. Guidelines recommend using an initial assessment of nodule probability of malignancy (pCA). A previous study found that despite this recommendation, physicians did not follow guidelines. METHODS: Physician assessments (N = 337) and two previously validated risk model assessments of pretest probability of cancer were evaluated for performance in 337 patients with pulmonary nodules based on final diagnosis and compared. Physician-assessed pCA was categorized into low, intermediate, and high risk, and the next test ordered was evaluated. RESULTS: The prevalence of malignancy was 47% (n = 158) at 1 year. Physician-assessed pCA performed better than nodule prediction calculators (area under the curve, 0.85 vs 0.75; P < .001 and .78; P = .0001). Physicians did not follow indicated guidelines when selecting the next test in 61% of cases (n = 205). Despite recommendations for serial CT imaging in those with low pCA, 52% (n = 13) were managed more aggressively with PET imaging or biopsy; 12% (n = 3) underwent biopsy procedures for benign disease. Alternatively, in the high-risk category, the majority (n = 103 [75%]) were managed more conservatively. Stratified by diagnosis, 92% (n = 22) with benign disease underwent more conservative management with CT imaging (20%), PET scanning (15%), or biopsy (8%), although three had surgery (8%). CONCLUSIONS: Physician assessment as a means for predicting malignancy in pulmonary nodules is more accurate than previously validated nodule prediction calculators. Despite the accuracy of clinical intuition, physicians did not follow guideline-based recommendations when selecting the next diagnostic test. To provide optimal patient care, focus in the areas of guideline refinement, implementation, and dissemination is needed.
Data from: Management of pulmonary nodules by community pulmonologists
BACKGROUND: Pulmonary nodules (PNs) are a common reason for referral to pulmonologists. The majority of data for the evaluation and management of PNs is derived from studies performed in academic medical centers. Little is known about the prevalence and diagnosis of PNs, the use of diagnostic testing, or the management of PNs by community pulmonologists. METHODS: This multicenter observational record review evaluated 377 patients aged 40 to 89 years referred to 18 geographically diverse community pulmonary practices for intermediate PNs (8-20 mm). Study measures included the prevalence of malignancy, procedure/test use, and nodule pretest probability of malignancy as calculated by two previously validated models. The relationship between calculated pretest probability and management decisions was evaluated. RESULTS: The prevalence of malignancy was 25% (n = 94). Nearly one-half of the patients (46%, n = 175) had surveillance alone. Biopsy was performed on 125 patients (33.2%). A total of 77 patients (20.4%) underwent surgery, of whom 35% (n = 27) had benign disease. PET scan was used in 141 patients (37%). The false-positive rate for PET scan was 39% (95% CI, 27.1%-52.1%). Pretest probability of malignancy calculations showed that 9.5% (n = 36) were at a low risk, 79.6% (n = 300) were at a moderate risk, and 10.8% (n = 41) were at a high risk of malignancy. The rate of surgical resection was similar among the three groups (17%, 21%, 17%, respectively; P = .69). CONCLUSIONS: A substantial fraction of intermediate-sized nodules referred to pulmonologists ultimately prove to be lung cancer. Despite advances in imaging and nonsurgical biopsy techniques, invasive sampling of low-risk nodules and surgical resection of benign nodules remain common, suggesting a lack of adherence to guidelines for the management of PNs.
Data from: Assessment of plasma proteomics biomarker's ability to distinguish benign from malignant lung nodules
Background: Lung nodules are a diagnostic challenge, with an estimated yearly incidence of 1.6 million in the United States. This study evaluated the accuracy of an integrated proteomic classifier in identifying benign nodules in patients with a pretest probability of cancer (pCA) ≤ 50%. Methods: A prospective, multicenter observational trial of 685 patients with 8- to 30-mm lung nodules was conducted. Multiple reaction monitoring mass spectrometry was used to measure the relative abundance of two plasma proteins, LG3BP and C163A. Results were integrated with a clinical risk prediction model to identify likely benign nodules. Sensitivity, specificity, and negative predictive value were calculated. Estimates of potential changes in invasive testing had the integrated classifier results been available and acted on were made. Results: A subgroup of 178 patients with a clinician-assessed pCA ≤ 50% had a 16% prevalence of lung cancer. The integrated classifier demonstrated a sensitivity of 97% (CI, 82-100), a specificity of 44% (CI, 36-52), and a negative predictive value of 98% (CI, 92-100) in distinguishing benign from malignant nodules. The classifier performed better than PET, validated lung nodule risk models, and physician cancer probability estimates (P < .001). If the integrated classifier results were used to direct care, 40% fewer procedures would be performed on benign nodules, and 3% of malignant nodules would be misclassified. Conclusions: When used in patients with lung nodules with a pCA ≤ 50%, the integrated classifier accurately identifies benign lung nodules with good performance characteristics. If used in clinical practice, invasive procedures could be reduced by diverting benign nodules to surveillance. Trial Registry: ClinicalTrials.gov; No.: NCT01752114; URL: www.clinicaltrials.gov).
Text-fig. 1: Topographical location of the Fukov gravel pit. in Fossils In Late Cretaceous To Early Palaeocene Flint Nodules Embedded In Pleistocene Glaciofluvial Sediments Near Fukov (Děčín District, Northern Bohemia)
Text-fig. 1: Topographical location of the Fukov gravel pit.
Figure 5 from: Larsen K (2011) Tanaidaceans (Crustacea) from the Central Pacific Manganese Nodule Province. I. The genera Collettea, Robustochelia and Tumidochelia. ZooKeys 87: 19-41. https://doi.org/10.3897/zookeys.87.784
Figure 5 - Tumidochelia tuberculata sp. n. Holotype A dorsal view B lateral view Scale bar 0.5 mm.
Neve David - Flint Nodule II
The artifact is included in this paper: https://www.sciencedirect.com/science/article/pii/S1040618217302185 Neve David is an Early Epipaleolithic site located at the foot of the western slope of the Mount Carmel hills in northern Israel. It was inhabited in the later part of the Early Epipaleolithic, about 15,000–13,000 BC. https://en.wikipedia.org/wiki/Neve_David Photography and photogrammetry - Eli Crater Gershtein Source: Objaverse 1.0 / Sketchfab
Respiration Gated Laser Guided CT Lung Nodule Biopsy
ClinicalTrials.gov study NCT01236937. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ultrasound and Cytological Evaluation 3 Years After Radiofrequency Thermal Ablation of Benign Thyroid Nodules : a Prospective Exploratory Cohort of 180 Nodules
ClinicalTrials.gov study NCT05726981. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule
ClinicalTrials.gov study NCT05003856. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules
ClinicalTrials.gov study NCT03183752. IPD Sharing: NO. Countries: 1. Publications: 0.
MDCT vs. CBCT Guided Percutaneous Lung Nodule Biopsy: A Comparison of Pneumothorax Incidence and Associated Risk Factors
ClinicalTrials.gov study NCT05344430. IPD Sharing: NO. Countries: 1. Publications: 0.
Noninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics
ClinicalTrials.gov study NCT07399210. IPD Sharing: YES. Countries: 1. Publications: 0.
Quantification of microRNAs in Diagnosis of Pulmonary Nodules
ClinicalTrials.gov study NCT03293433. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Human-AI Collaboration for Ultrasound Diagnosis of Thyroid Nodules - a Clinical Trial
ClinicalTrials.gov study NCT06306599. IPD Sharing: NO. Countries: 1. Publications: 0.
Application of Extended Reality (XR)-Assisted CT-Guided Localization of Pulmonary Nodules in Thoracoscopic Sublobar Resection.
ClinicalTrials.gov study NCT06976684. IPD Sharing: NO. Countries: 0. Publications: 0.
Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules
ClinicalTrials.gov study NCT06215885. IPD Sharing: NO. Countries: 1. Publications: 0.
A Prospective, Non-interventional Cohort Study of Subsolid Pulmonary Nodules
ClinicalTrials.gov study NCT06458673. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Myo-inositol and Selenium in Indeterminate Thyroid Nodules (TIR3a)
ClinicalTrials.gov study NCT06736015. IPD Sharing: YES. Countries: 1. Publications: 0.
Diagnostic Significance of CTCs in Patients With Thyroid Nodules (Circulating Tumor Cells)
ClinicalTrials.gov study NCT03772496. IPD Sharing: NO. Countries: 1. Publications: 0.
The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children
ClinicalTrials.gov study NCT03040596. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.